Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
The extent of evidence supporting the most widely used, first-line drug for type 2 diabetes, metformin, was the topic under discussion during the Michael Berger debate on the closing day of this year's European Association for the Study of Diabetes (EASD) 2014 Meeting.
Synthesized in 1922, with its first trial in 1957, metformin has been available in Europe since 1960 but made its debut in the United States only in 1995. Arguing for the motion, Metformin: Where is the evidence? Rury Holman, MD, director of the University of Oxford Diabetes Trials Unit, United Kingdom, said it isn't clear that there is sufficient proof to support metformin use: "If it were clear, we wouldn't be having this debate."
Against the motion, claiming that the existing evidence supports first-line use of metformin, was Harold Lebovitz, MD, professor of medicine at the division of endocrinology and metabolism/diabetes at the State University of New York Health Center, Brooklyn, NY.
http://www.medscape.com/viewarticle/832311
(free registration required)
Synthesized in 1922, with its first trial in 1957, metformin has been available in Europe since 1960 but made its debut in the United States only in 1995. Arguing for the motion, Metformin: Where is the evidence? Rury Holman, MD, director of the University of Oxford Diabetes Trials Unit, United Kingdom, said it isn't clear that there is sufficient proof to support metformin use: "If it were clear, we wouldn't be having this debate."
Against the motion, claiming that the existing evidence supports first-line use of metformin, was Harold Lebovitz, MD, professor of medicine at the division of endocrinology and metabolism/diabetes at the State University of New York Health Center, Brooklyn, NY.
http://www.medscape.com/viewarticle/832311
(free registration required)